PREVAIL (Follow-up)

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who Are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies